Synergistic effect of combined intraperitoneal cisplatin and cytosine arabinoside in a murine ovarian cancer model.

摘要: The chemotherapeutic combination of cisplatin and cytosine arabinoside has synergy in vitro. We used a murine ovarian teratocarcinoma C3HeB/FeJ mice to evaluate these drugs for vivo. Several dose-response schedules various sequences were tested determine the optimal delivery schedule. Survival control injected with 10(4) was 28 days. Tumor-bearing treated intraperitoneal alone had significantly prolonged survival, whereas did not prolong survival. Repeated doses every 24 hours 4 days resulted minimal prolongation Simultaneous one-time administration as measured by 50% surviving at 80 Combined simultaneous daily 3 100% survival 120 Both have an outstanding pharmacokinetic advantage when given intraperitoneally. A clinical trial 3-day schedule is warranted.